{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:02:45Z","timestamp":1746417765491,"version":"3.40.4"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Previous meta-analyses have indicated that peficitinib was the promising agent for the treatment of rheumatoid arthritis (RA). Meanwhile, a recent network meta-analysis has further investigated the comparative efficacy of different peficitinib regimes. However, pooled results from previous network meta-analysis must be cautiously interpreted because 2 eligible studies were missed. Therefore, we designed this updated network meta-analysis to further establish the optimal dosage of peficitinib in treating RA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We will carry out a network meta-analysis of randomized controlled trials (RCTs) with Markov Chain Monte Carlo method in order to merge direct and indirect evidence. We will identify potentially eligible studies through searching 4 databases including PubMed, Embase, Cochrane Library, and China National Knowledgement Infrastructure (CNKI) until to December 2020. We will make this network meta-analysis following the process recommended by the Cochrane Handbook.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>As a systematic and chronic autoimmune disease, RA primarily was characterized by persistent synovitis, progressive joint injury, and deformity. Patients who were identified as RA will experience a series of adverse consequences such as disability and poor quality of life (QoL). Peficitinib, one of the Janus kinases (JAKs) inhibitors, has been suggested to be effective in treating active RA by numerous clinical studies and meta-analyses. Although a recent meta-analysis investigated the comparative efficacy of different dosages of peficitinib, reliable results cannot be obtained because it missed 2 critical eligible studies. We designed this updated network meta-analysis through including all eligible studies to further ask which dosages may be the preferred option for treating active RA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ethics and dissemination:<\/jats:title>\n            <jats:p>No ethics approval and informed consent will be required in our meta-analysis. Our findings in this updated network meta-analysis will be disseminated via conferences and academic journal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Open Science Framework (OSF) Registration DOI Number:<\/jats:title>\n            <jats:p>This protocol of updated network meta-analysis has been registered in Open Science Framework (OSF) system on January 8, 2021. The unique registration DOI number of 10.17605\/OSF.IO\/YSPM6 has been approved for our protocol (accessible at: https:\/\/osf.io\/yspm6).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024586","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T21:22:11Z","timestamp":1614374531000},"page":"e24586","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The optimal dosage of pefcitinib for the treatment of active rheumatoid arthritis"],"prefix":"10.1097","volume":"100","author":[{"given":"Yuyi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunfang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-5546","authenticated-orcid":false,"given":"Chunyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/ard.2008.102822","article-title":"Methotrexate: the gold standard without standardisation","volume":"68","author":"Kay","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1056\/NEJMra040226","article-title":"Therapeutic strategies for rheumatoid arthritis","volume":"350","author":"O\u2019Dell","year":"2004","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"Use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin Ther"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.3899\/jrheum.130767","article-title":"Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?","volume":"41","author":"Ciubotariu","year":"2014","journal-title":"J Rheumatol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14656566.2020.1739649","article-title":"Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials","volume":"21","author":"Tanaka","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jb\/mvv069","article-title":"Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside","volume":"158","author":"Tanaka","year":"2015","journal-title":"J Biochem"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1080\/14656566.2016.1241237","article-title":"Chemical JAK inhibitors for the treatment of rheumatoid arthritis","volume":"17","author":"Nakayamada","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"(suppl)","key":"R11-20250504","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/rheumatology\/key280","article-title":"The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?","volume":"58","author":"Tanaka","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/art.11096","article-title":"Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues","volume":"48","author":"van der Pouw Kraan","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/ard.2005.037929","article-title":"Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis","volume":"65","author":"Walker","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/rheumatology\/keu430","article-title":"The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels","volume":"54","author":"Isom\u00e4ki","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jcpt.13142","article-title":"Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis","volume":"45","author":"Lee","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials","volume":"78","author":"Xie","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R17-20250504","first-page":"859","article-title":"Efficacy and safety of peficitinib for treating rheumatoid arthritis: a systematic review","volume":"31","author":"Liu","year":"2020","journal-title":"China Pharm"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40261-019-00863-9","article-title":"Comparative efficacy and safety of Peficitinib 25, 50, 100, and 150\u200amg in patients with active rheumatoid arthritis: a bayesian network meta-analysis of randomized controlled trials","volume":"40","author":"Lee","year":"2020","journal-title":"Clin Drug Investig"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"System Rev"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.1780350502","article-title":"The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis","volume":"35","author":"Hochberg","year":"1992","journal-title":"Arthritis Rheum"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/art.24123","article-title":"Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR\/ACR collaborative recommendations","volume":"59","author":"Aletaha","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R27-20250504","first-page":"S38","article-title":"Cochrane handbook for systematic reviews of interventions version 5.0.0","volume":"5","author":"Higgins","year":"2008","journal-title":"Naunyn-Schmiedebergs Archiv"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","article-title":"Publication bias in clinical research","volume":"337","author":"Easterbrook","year":"1991","journal-title":"Lancet"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res Synth Methods"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/art.40054","article-title":"Peficitinib, a JAK Inhibitor, in Combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.39955","article-title":"Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate","volume":"69","author":"Kivitz","year":"2017","journal-title":"Arthritis Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:15:28Z","timestamp":1746339328000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024586"}},"subtitle":["A protocol for an updated network meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024586","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,2,19]]},"assertion":[{"value":"2021-01-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}